Capital Investment Counsel Inc Buys 210 Shares of Hologic, Inc. (NASDAQ:HOLX)

Capital Investment Counsel Inc boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,724 shares of the medical equipment provider’s stock after acquiring an additional 210 shares during the quarter. Capital Investment Counsel Inc’s holdings in Hologic were worth $351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the first quarter worth about $37,000. Mather Group LLC. bought a new stake in shares of Hologic in the 1st quarter worth approximately $48,000. Massmutual Trust Co. FSB ADV increased its stake in shares of Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the period. Toth Financial Advisory Corp increased its stake in shares of Hologic by 81.1% during the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 347 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Hologic by 145.3% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 468 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by insiders.

Analyst Ratings Changes

HOLX has been the topic of several research reports. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $0.44 during midday trading on Tuesday, reaching $80.91. The stock had a trading volume of 1,425,513 shares, compared to its average volume of 1,653,221. The company has a market capitalization of $18.88 billion, a price-to-earnings ratio of 41.28, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The stock has a 50-day moving average of $77.27 and a 200-day moving average of $76.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.29 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 EPS. As a group, research analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.